Onco-hematology Molecular Testing Market Top Players - Asuragen, Inc., Bio-Rad Laboratories, Inc., ICON plc, Illumina, Inc., Integrated DNA Technologies.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Onco-hematology Molecular Testing Market- (By Blood Cancer Type, (Chronic Myeloid Leukemia, (Polycythemia Vera, Essential, Thrombocythaemia, Myelofibrosis), Myeloproliferative Neoplasms, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia), By Technology (qPCR, dPCR, Next-Generation Sequencing, Others), By Blood Cancer Biomarker(BCR-ABL1 Mbcr, JAK2, CALR, MPL, PML-RARA, NPM1, RUNX1-RUNX1T1, CBFB-MYH11, BCR-ABL1 mbcr), By End-user (National Reference Lab / Specialty Lab, University Hospital / Oncology Center, Community Hospital / IDN (Regional/National))) Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global Onco-hematology Molecular Testing Market is valued at US$ 497.67 Mn in 2022, and it is expected to reach US$ 1280.06 Mn by 2031, with a CAGR of 11.2% during a forecast period of 2023-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1995

Hemato-oncology is the branch of science focused on the diagnosis, treatment, and prevention of blood-related conditions, including cancers such as lymphoma and myeloma. The growing prevalence of lymphoma and myeloma is expected to drive market growth during the forecast period. According to the American Cancer Society, Non-Hodgkin lymphoma (NHL) is one of the most common cancer types, accounting for approximately 4.0% of all cancer cases in the United States. Oncology molecular diagnostics is a field that analyzes the biological molecules in cancer cells to detect and assess cancer. This process involves the identification and measurement of specific genetic sequences in DNA, RNA, and cellular proteins through various tests using blood, saliva, and tissue samples from cancerous growths. These diagnostics provide rapid analysis and deliver detailed insights, which are then used to tailor personalized cancer treatments. Oncology molecular diagnostics are employed in both point-of-care (POC) and clinical cancer detection tests. Additionally, blood banks use blood samples to detect pathogens and infectious diseases.

List of Prominent Players in the Onco-hematology Molecular Testing Market:
• Asusragen, Inc.
• Bio-Rad Laboratories, Inc.
• ICON plc
• Illumina, Inc.
• Integrated DNA Technologies, Inc. (ArcherDx, Inc.)
• Invivoscribe, Inc.
• QIAGEN N.V.
• Thermo Fisher Scientific, Inc.
• Cepheid

Market Dynamics:
Drivers-
The global oncology molecular diagnostics market is expected to experience significant growth due to several factors, including the increasing prevalence of various cancers, the shift toward precision medicine, growing demand for preventive care, the adoption of advanced and automated cancer diagnostic techniques, and favorable health reimbursement policies. According to the World Health Organization, an estimated 18.0 million new cancer cases were diagnosed globally in 2018, a figure that is expected to further accelerate the growth of the oncology molecular diagnostics market. However, challenges such as the high costs associated with molecular diagnostics, budgetary constraints, and the need for specialized facilities may hinder the market's expansion.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04

Challenges:
The global availability of hospital resources for cancer care was significantly impacted by the COVID-19 pandemic. A study published in Haematological Oncology in October 2022 highlighted that the pandemic caused substantial disruptions in oncology practices worldwide, including the management of lymphoma, placing a considerable burden on both patients and healthcare providers and potentially worsening patient outcomes. Additionally, a study conducted in the United States and published in the Journal of Clinical Oncology in September 2022 reported a 22% decrease in new diagnoses of multiple myeloma during the early stages of the pandemic. However, by the later stages of the pandemic, there was a noticeable increase in demand for cancer diagnostics, particularly for hematological cancers.

Regional Trends:
North America plays a pivotal role in regional market growth and significantly contributes to global sales. This market dominance is primarily driven by the high incidence of hematologic cancers, an aging population, heightened awareness of new treatment options, and the strong presence of industry players in the region. The rising prevalence of leukemia, lymphoma, and multiple myeloma is further fueling industry expansion in North America. For example, data from the Canadian Cancer Society for 2022 revealed that approximately 6,700 Canadians were diagnosed with leukemia in 2021, with 4,000 cases among men and 2,700 cases among women.

Recent Developments:
• In Mar 2023, Servier and QIAGEN partnered to create a new mIDH1 companion diagnostic test to help Servier's onco-hematology portfolio. This test was used with Servier's tailored treatments for Acute Myeloid Leukaemia (AML) that were on the market and still being researched.
• In Apr 2021, Kartos Therapeutics and Illumina announced a new oncology partnership to create a TP53 companion diagnostic based on NGS. The TSO 500 with peripheral whole blood as a diagnostic sample type was first used in this companion diagnostic for various hematologic purposes.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1995

Segmentation of Onco-hematology Molecular Testing Market-
• Blood Cancer Type
o Chronic Myeloid Leukemia
 Polycythemia Vera
 Essential Thrombocythaemia
 Myelofibrosis
o Myeloproliferative Neoplasms
o Acute Myeloid Leukemia
o Acute Lymphoblastic Leukemia
• Technology
o qPCR
o dPCR
o Next-Generation Sequencing
o Others
• Blood Cancer Biomarker
o BCR-ABL1 Mbcr
o JAK2
o CALR
o MPL
o PML-RARA
o NPM1
o RUNX1-RUNX1T1
o CBFB-MYH11
o BCR-ABL1 mbcr
• End-user
o National Reference Lab / Specialty Lab
o University Hospital / Oncology Center
o Community Hospital / IDN (Regional/National)
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/onco-hematology-molecular-testing-market/1995

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.